Chinese biotech firm Innovent Biologics is looking to raise up to $422 million in its Hong Kong IPO, three sources said, in what could be the biggest biotech IPO in the financial hub this year. Innovent, which is backed by mutual fund giant Fidelity and Singapore state investor Temasek, has... Read more »
The post Temasek-backed Chinese firm Innovent Biologics plans $422m HK IPO appeared first on DealStreetAsia.